Acute and long-term treatments for neuromyelitis optica
DOI:
https://doi.org/10.56294/sctconf2024.1115Keywords:
Devic syndrome, Demyelination, Autoimmune disease, TreatmentAbstract
Introduction: Spectrum neuromyelitis optica has been an autoimmune disease of the central nervous system that presents challenges in both diagnosis and treatment. The complex pathophysiology, together with varied clinical manifestations, makes its management especially critical. Therefore, the present study has focused on describing and analyzing spectrum neuromyelitis optica, by focusing on the pathophysiology, clinical presentation and therapeutic options. As well as the understanding and management of the disease in medical practice.
Method: A descriptive bibliographic review of the current literature on NMOSD was carried out, covering studies on the pathophysiology, clinical presentation and therapeutic strategies used.
Results: Severe demyelination in NMOSD was observed to be mediated by antibodies against aquaporin-4, leading to significant axonal damage. Acute therapies, such as intravenous methylprednisolone and plasmapheresis, as well as long-term treatments, such as mycophenolate mofetil and rituximab, have shown efficacy in managing the disease. Furthermore, early diagnosis and appropriate treatment turned out to be essential to improve patients' quality of life.
Conclusions: The research highlighted the need for early diagnosis and a multimodal therapeutic approach for NMOSD. The combination of current treatments and the continued need for research to develop new therapeutic options are essential to advance the treatment of the disease
References
1. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-76.
2. Torres-Criollo LM, Molina-González KA, Andrade-Campoverde MJ, Castro-Campoverde MA. Neuromyelitis optica spectrum disorder diagnostic-therapeutic update. Systematic review. Archivos Venezolanos de Farmacologia y Terapeutica. 2022;41(5):353.
3. Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of NMO: A systematic review. Neurology. 2020;96(2):59-77.
4. Sousa JMMd, Moura CLd, Barbosa HDC, Sousa TMLd, Garcia LM, Miranda GdA, et al. Neuromielite óptica, esclerose sistêmica e morfeia: uma revisão integrativa. eOftalmo. 2022;8(1):3-9.
5. Chan K-H, Lee C-Y. Treatment of Neuromyelitis Optica Spectrum Disorders. International Journal of Molecular Sciences. 2021;22(16):8638.
6. Alves P, Miranda Ranucci M, Gabriella K, Rocha Y, Antune Santoss PT, Cardoso de Castro Magalhães I, et al. Perspectivas para o tratamento da neuromielite óptica: uma revisão de literatura. Brazilian Journal of Implantology and Health Sciences. 2024;6(7):2859-65.
7. Alcubierre R, Sánchez Dalmau BF, Muñoz S. La esclerosis múltiple en oftalmología: más allá de la neuritis óptica. Medicina Clínica. 2020;155(2):70-6.
8. Gomes ABAGR, Adoni T. Differential diagnosis of demyelinating diseases: what's new? Arquivos de Neuro-Psiquiatria. 2022;80(5 suppl 1):137-42.
9. Ashraf H, Solla P, Sechi LA. Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. Pharmaceuticals. 2022;15(9):1077.
10. Ceglie G, Papetti L, Valeriani M, Merli P. Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences. 2020;21(15):5304.
11. Waliszewska Prosół M, Chojdak Łukasiewicz J, Budrewicz S, Pokryszko Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects. International Journal of Molecular Sciences. 2021;22(6):2801.
12. Fernández Ó, Montalban X, Agüera E, Benito YA, Alonso A, Arroyo R, et al. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I). Revista de neurología. 2024;79(1):21-9.
13. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology. 2020;11(June):1-6.
14. dos Passos GR, Adoni T, Mendes MF, Sato DK. Remodelando a neuroimunologia: diagnóstico e tratamento na era da medicina de precisão. Arquivos de Neuro-Psiquiatria. 2024;81(12):1125-33.
15. Ortiz Salas PA, Gaviria Carrillo M, Cortés Bernal GA, Moreno Medina K, Roa LF, Rodríguez Quintana JH. Espectro de neuromielitis óptica: ¿seropositivo para la anticuaporina es una entidad diferente de los pacientes que son seronegativos? Una perspectiva de Colombia. Neurología. 2020;38(7):504-10.
16. Tramullas J. Temas y métodos de investigación en Ciencia de la Información, 2000-2019. Revisión bibliográfica. El profesional de la información. 2020;29(4):2-6.
17. Zhang C, Tian L, Chu H. Usage frequency and application variety of research methods in library and information science: Continuous investigation from 1991 to 2021. Information Processing and Management. 2023;60(6):4-8.
18. Granikov V, Hong QN, Crist E, Pluye P. Mixed methods research in library and information science: A methodological review. Library & Information Science Research. 2020;42(1):3-6.
Published
Issue
Section
License
Copyright (c) 2024 Piedad Elizabeth Acurio Padilla , Danny Stuart Bohórquez Rivera , Fernanda Latorre Barragán , Olivia Elizabeth Altamirano Guerrero (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
